2929.T

The company maintains a liquidity position with a current ratio of 1.19, indicating a moderate ability to meet short-term obligations. Its price-to-book ratio is 1.62, suggesting that the market values the company at a premium to its book value. The company's price-to-earnings ratio is 50.83, which is relatively high, indicating that investors are paying a significant multiple for each yen of earnings.

Profitability metrics show a return on equity of 3.19% and a return on assets of 1.13%, both of which are below the typical thresholds for strong performance in the biotechnology and medical research industry. The company's operating income of 2.25 billion JPY and net income of 368 million JPY reflect a narrow profit margin, which is a concern given the high capital intensity of the industry.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the risk associated with market fluctuations in the healthcare diagnostics sector.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The operating cash flow is negative at -1.09 billion JPY, and the free cash flow is also negative at -537 million JPY, indicating that the company is not generating sufficient cash from operations to fund its capital expenditures.

The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The negative net cash position after subtracting total debt suggests that the company may need to raise additional capital in the near term, which could lead to dilution of existing shareholders.

Recent events include the filing of the latest financial statements, which show a revenue of 65.26 billion JPY and a gross profit of 52.58 billion JPY. No significant earnings surprises or management guidance changes were reported in the latest transcripts.